Marc is founder of BioVersys AG, a multi-award winning biopharmaceutical company focused on combatting antimicrobial resistance. Prior to BioVersys, he completed his studies in Biology at the University of Freiburg (Germany) and the University of Queensland (Australia). He holds a PhD in Biotechnology from the ETH Zurich. Marc gained additional business experience as Associate Intern at McKinsey & Company and insights to intellectual property rights at the patent offices Ernest T. Freylinger SA (Luxemburg) and Joachim Stuercken GmbH (Germany). Marc is winner of two Venture Leaders awards (2008 and 2016) and he is Vice President of the Board of the BEAM Alliance.
Dr. Sergio Lociuro
Chief Scientific Officer
Sergio received his Laurea degree in Chemistry at the University of Rome, Italy in 1981 and, after a two-year postdoctoral fellowship at the Italian Research National Countil, he moved t o UNB, Canada, where he received his Ph.D in 1987. In the same year he started his career in the pharmaceutical industry as a medicinal chemist. In his almost 30 years experience in major pharmaceutical companies and SMEs, Sergio has held positions such as Director of Medicinal Chemistry and International Project Leader in GSK, Head of Peptide Epitope Mimetics in Polyphor Ltd and Head of Research and Scientific Communication in Arpida AG and has been part of the Board of Directors of Arpida A/S. Founder of THOT consulting Sagl, a Swiss consulting firm providing services in the Research and Development of anti-infectives and pharmaceutical drugs in general, he has lately held the position of CSO in C10 Pharma and Adenium Biotech, two Scandinavian biotech companies. His background spans from early drug discovery to late preclinical development. He has conducted Phase I clinical studies, participated in late clinical studies and in discussions with both the US FDA and EMA.
Dr. Jonathan J. Butcher
Head Business Development & Alliance Management
Jonathan joined BioVersys in May 2018. Prior to which he was Head of Business Development for Polyphor’s Drug Discovery Unit, where he secured drug discovery collaboration & licensing deals with leading global pharmaceutical and biotech companies. At Polyphor he also led the valuation of Polyphor’s pipeline assets, Murepavidin (POL7080) - Phase III Pseudomonas aeruginosa selective antibiotic, licensed to Roche in 2013, US$547 million and POL6014 - Phase Ib selective elastase inhibitor for respiratory diseases, licensed to Santhera in 2018, US$130 million. Prior to Polyphor, Jonathan led Hit-2-Lead and medicinal chemistry projects at Evotec, UK, for pharmaceutical clients. He obtained his Ph.D. in organic chemistry from the University of Reading, England and conducted post-doctoral research studies at Cardiff University, Wales.
Dr. Glenn E. Dale
Chief Development Officer
Glenn is a distinguished expert in infectious diseases, author of numerous publications, and inventor on many patents. Since February 2019 Glenn leads the clinical development activities at BioVersys, applying his 25 years of R&D experience and significant knowledge in the modern development of antibiotics. Glenn obtained his Ph.D. in Biochemistry in 1993 from the University of Basel. Following post-doctoral studies in Basel he has held the following positions; Group Leader at Roche, Head of Biology, Site Head at Morphochem AG and Scientific coordinator responsible for Pre-clinical research at Arpida. In 2009 he joined Polyphor where he led the Antibiotic Research and Early Development, successfully transitioning Murepavadin (POL7080) from pre-clinical activities to Phase 3 studies. Glenn is an expert in developing and implementing antibiotic clinical development plans (e.g. devising pathogen specific development) and is experienced in presenting to and discussing with European and US regulatory authorities, e.g. scientific advice meetings (MHRA, EMA), Type C meetings (FDA) and End of Phase 2 meeting (FDA).